We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
TVGN

Price
1.20
Stock movement down
-0.01 (-1.63%)
Company name
Tevogen Bio Holdings Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsværdi
177.82M
Ent værdi
-
Pris/omsætning
-
Pris/bog
-
Udbytte afkast
-
Udbyttevækst
-
Vekst år
-
FCF-udbetaling
-
Efterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års afkast
39.08%
3 års afkast
-
5 års afkast
-
10 års afkast
-
Senest opdateret: 2025-09-15

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UDBYTTE

TVGN betaler ikke udbytte

VÆRDIANSÆTTELSE

Værdiansættelsesforhold

Loading...
Værdiansættelsesforhold-data
Efterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Værdiansættelse (salg/bogført værdi)

Loading...
Værdiansættelse (salg/bogført værdi)-data
Pris til omsætning-
Pris til egenkapital-
EV i forhold til salg-

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

ØKONOMI

iO Charts is a Seeking Alpha partner

INFORMATION OM AKTIER

Aktiediagram

Loading...
Aktiekurs-data
Åbning0.91
Daglig høj0.93
Daglig lav0.90
Daglig volumen217K
Højeste gennem alle tider10.00
1 års analytiker estimat10.00
Beta-0.75
EPS (TTM)-
Udbytte pr. aktie-
Ex-div dato-
Næste dato for resultatpræsentation-

Nedsidepotensial

Loading...
Nedsidepotensial-data
TVGNS&P500
Nuværende prisfald fra top notering-90.96%-1.46%
Højeste prisfald-97.41%-56.47%
Højeste efterår dato9 Oct 20249 Mar 2009
Gennemsnitlig fald fra toppen-83.88%-10.99%
Gennemsnitlig tid til nyt højdepunkt96 days12 days
Maks. tid til nyt højdepunkt380 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

OPLYSNINGER OM VIRKSOMHEDEN
TVGN (Tevogen Bio Holdings Inc) company logo
Markedsværdi
177.82M
Markedsværdi kategori
Small-cap
Beskrivelse
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920 which is in preclinical trial for treating cervical cancer; TVGN 960 which is in preclinical trial for treating oropharyngeal cancer; TVGN 601 which is in preclinical trial for treating multiple sclerosis; TVGN 930 which is in preclinical trial for treating Epstein-Barr virus associated lymphomas; and TVGN 116 a product candidate targeted at hepatitis B and is in preclinical trial. Tevogen Bio Holdings Inc. was formerly known as Tevogen Bio Inc. and changed its name to Tevogen Bio Holdings Inc. in February 2024. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Personale
18
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
USA
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FORSTÅ FORRETNINGEN
Loading...